News center
On July 24, SDM Bioserices and Australia JP Medical Consulting Pty Ltd (hereinafter referred to as "JP Medical Consulting") announced a strategic cooperation. The cooperation aims to make full use of the clinical resources and professional advantages of the two sides in the field of medicine in China and Australia, promote the internationalization of clinical trials and new drug research and development, and provide one-stop services for Chinese biopharmaceutical enterprises in Australian clinical trials.
Founded in 2005, SDM Bioserices is a contract research organization (CRO) that provides full-process clinical research and registration services. The company is headquartered in Beijing, after years of development, has set up offices in a number of major cities in China, and overseas such as the United States, Singapore, Malaysia and other places to carry out business, active layout in Australia, New Zealand business. SDM Bioserices has a team of more than 1,000 people dedicated to providing clinical services in the fields of therapeutic drugs, vaccines, nuclear drugs and medical devices.
JP Medical Consulting is a professional RCO (Research Consulting Organisation) medical consulting company registered in Australia, committed to providing Australian clinical trial services for Chinese biomedical enterprises. Established by a clinical medical expert team led by senior executives in the pharmaceutical industry and a number of top international experts, academicians of the Australian Academy of Sciences and the Australian Academy of Health and Medical Sciences. The expert advisory team includes Professor Ian Frazer, inventor of Gardasil®, the world's first HPV cervical cancer vaccine. Professor Mark von ltzstein, inventor of Relenza®, the world's first anti-influenza drug; and internationally renowned tumor immunologist Chris Parish professor, registered experts and a senior elite R&D tax refund team that can provide the whole process of R&D tax refund services.
Australia has the advantages of a unique clinical trial ecosystem, world-class clinical research infrastructure, a supportive regulatory system, experienced researchers and government incentives of up to 43.5% cash tax rebate. Australian clinical trial data is recognized by major global drug authorities, including the US FDA and the European EMA, helping to support international filings and regulation. Australia's regulatory approval process for clinical trials is fast and pragmatic, typically taking only three to four months from the submission of an ethical review to the first participant enrollment, and Australia's ethnic diversity means that potential differences between different ethnic groups can be observed early in clinical trials, providing important data support for global marketing. This has also made Australia one of the most desirable locations in the world to conduct clinical trials, and many Chinese pharmaceutical companies use Australia as their first stop to help companies complete the sea.
DR. Yu Wen, Senior Vice President and CBO of SDM Bioserices, said:
"The cooperation between SDM and the" Father of Cervical Cancer Vaccine "team of JP Medical Consulting Australia will further enhance SDM's competitiveness in the international market. JP Medical Consulting has a wide range of medical resources and professional medical consulting team in Australia, which can provide guidance and strong support for the clinical trial services in the field of therapeutic drugs, preventive and therapeutic vaccines." SDM has been in the clinical trial and registration service industry for nearly 20 years, and the two sides will lead more companies with overseas needs to carry out clinical trials in Australia through resource sharing, technical exchanges and project cooperation.
Dr. Mok Zhaojun, general manager of Shanghai SDM, said:
"We are very pleased to have reached a strategic partnership between SDM Bioserices and JP Medical Consulting. As a CRO which focusing on clinical research and registration services in the field of vaccines, Shanghai SDM will make full use of the framework of this cooperation to strengthen the layout of Shanghai SDM in the global vaccine research and development network. By sharing JP Medical Consulting's rich experience and resources in Australia and seamlessly connecting with Australia's advanced clinical trial resources, we will help Chinese vaccine companies to implement their overseas strategy, accelerate the internationalization process of Chinese vaccine products, and ensure their rapid access and wide application in the global market."
Dr. Bao Yuanwu, general manager of the ShouYan of Shanghai and Beijing, said:
"As the company's core subsidiary focused on early stage clinical trials and central laboratory business, the strategic partnership with JP Medical Consulting marks a significant broadening of our vision in the field of international pharmaceutical research and development, and a valuable opportunity to deeply exchange and learn with top international teams." At the critical stage of clinical trials, accurate and efficient sample analysis is invaluable in evaluating the efficacy, safety and pharmacokinetic properties of drugs. With JP Medical Consulting's extensive resources in Australia, we will fully upgrade and optimize our clinical sample analysis technology and service processes to ensure seamless alignment with international and standardized standards, and build a solid technical and quality barrier to undertake international clinical and bioanalysis business." Stam Pharma looks forward to working closely with JP Medical Consulting to jointly accelerate the internationalization of China's biomedical industry and create a new chapter!
Dr. Pang Jianhong, CEO of JP Medical Consulting, said:
"I had the honor to know and get the services of SDM when I worked as CMO in a domestic mRNA vaccine company, and I still remember SDM's professional ability and quality service in vaccine clinical trials." With SDM's rich experience in vaccine clinical services, we have mobilized various resources in China and Australia, and the combination of strong and strong will definitely provide first-class clinical trial services for Chinese biomedical enterprises in clinical trials in Australia." As an RCO, JP Medical Consulting has established extensive and in-depth cooperative relations with international and Australian clinical CROs at all levels, Australian Phase I trial centers, hospitals, clinical central laboratories, and various treatment TA platforms, and has a huge clinical resource base. It can provide tailored and precise configuration services for more Chinese biopharmaceutical enterprises in clinical trials in Australia.
About JP Medical Consultation in Australia
JP Medical consulting Pty Ltd: The Australian Register (ACN673 260 056) was created by a team of clinical medical experts led by senior executives in the pharmaceutical industry and a number of top international experts, academicians of the Australian Academy of Sciences and the Australian Academy of Health and Medical Sciences. Focusing on providing Australian clinical trial RCO and CRO services for Chinese biopharmaceutical enterprises, Including international clinical trial strategy expert guidance, clinical medical support, independent supervision of clinical trial operation, clinical CRO analysis and recommendation, clinical CRO management, Australian company registration and acting director services, clinical research and development tax refund process services (see https://jpmed.com.au).
KY-0301 is the world's first nano-dual-anti-ADC developed by Novatim based on its own innovative nano-dual-anti-ADC platform “TPEBEN”.
Beijing Shouyan Lab is certified by NGSP in the United States.
Provide diverse and better treatment options for patients worldwide.
At the intersection of the end of the year, we sincerely invite you to join us in focusing on the shining points of the year, and to look back together and cherish the bright moments that have illuminated our way forward in the past year.
On October 24-25 2024, Dr. Yuwen, CBO and SVP of SDM Bioservices, was invited to attend the 2024 International Biomedical Industry Innovation Beijing Forum co-sponsored by DIA and Beijing Advanced Medical Equipment Industry Innovation Alliance. The forum brings together representatives of global regulators, leading experts in biomedicine, industry leaders and academics to discuss the latest trends and industry innovations in global drug development.
AMWC China 2024 World Congress on Aesthetics and Anti-Aging was successfully carried out in Chengdu on October 18-20, 2024, with medical and aesthetic experts, scholars, and industry practitioners from all over the world participating and presenting their latest achievements.
On July 24, SDM Bioserices and Australia JP Medical Consulting Pty Ltd (hereinafter referred to as "JP Medical Consulting") announced a strategic cooperation. The cooperation aims to make full use of the clinical resources and professional advantages of the two sides in the field of medicine in China and Australia, promote the internationalization of clinical trials and new drug research and development, and provide one-stop services for Chinese biopharmaceutical enterprises in Australian clinical trials.
August 1, China, Beijing, Liu Xueliang, deputy secretary of the District Party Committee and district governor, led a team to visit key enterprises of Daxing biomedical Industry Base to investigate the development and construction of pharmaceutical research and development service platform enterprises.
On the way to further explore and promote the professional development of medical clinical trials, SDM and Tonghua Dongbao jointly successfully held a nine-month "Diabetes Professional CRA Series course".
On July 11-12, 2024, MedDRA MSSO successfully held the fourth offline face-to-face training of 2024 at the Shenyang office of SDM. As the organizer of this event, SM gathered together with more than 40 experts from various fields such as CRO, pharmaceutical companies and partners, including medical coders, data management and statistics, drug safety/pharmacovigilance, medical writers and other modules.
On July 3, 2024, SDM Bioservices and Shanghai Ruiningkang Bio-Pharmaceutical Technology Development Co., LTD. (" Ruiningkang Bio ") reached a strategic cooperation to work together to help innovative drugs in the quantitative pharmacology, dose exploration level, and promote more innovative drugs with global competitiveness to the market.
On November 21, 2023, Beijing Kangle Guard Biotechnology Co., Ltd. is affiliated with Muhammadiyah University Malang, Indonesia (at) to start the "restructuring nine price 6/11/16/18/31/33/45/52/58) human papilloma virus (HPV) vaccine (e. coli) phase III clinical trials into the group of vaccination. As a CRO focused on vaccine clinical trials, Shanghai SDM undertook the phase III clinical study of the vaccine project in Indonesia, responsible for project management, data management, biostatistical analysis, pharmacovigilance and other important work of the project.
The laboratories operated by SDM in the North and South have their own specialties and technical advantages. Among them, Beijing Shouyan, with several P2 and P2+ laboratories and complete PCR testing facilities, is one of the few testing organizations in China focusing on bioanalysis of vaccines and traditional Chinese medicines; Hangzhou Amador focuses on XDC, macromolecules, and CGT, etc., and provides one-stop bioanalytical services for ADC drugs, which is a technological leader in the industry.
Meiji has advanced its oral paclitaxel softgel capsule, MJC-001, to clinical trial stage. With support from SDM Bioservices, Meiji received FDA clearance for its Investigational New Drug (IND) application, positioning it among the leading developers of oral paclitaxel formulations.
Listen to Dr. Liping Shen: Innovating Vaccine Bioanalysis for Change
KY-001 is an oral small-molecule inhibitor targeting the YAP/TAZ-TEAD interaction in the Hippo pathway with a proposed indication for advanced solid tumors driven by Hippo dysregulation.
Get in touch with SDM experts for your questions or comments and a member of our team will get back to you directly.
Let's Start a Conversation
